• DESCRIPTION

CLART® HPV3 Kit detects up to 49 (6, 11, 16, 18, 26, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 74, 81, 82, 83, 84, 85, 86, 87, 89, 97, 101, 102, 103, 106, 150 and 151) of the most clinically relevant HPV types in a wide range of samples (swabs, cell suspensions, tissues fixed in FFPE).

Detection of the different HPV genotypes is achieved by PCR amplification of a 450 bp fragment within the highly conserved L1 region of the virus. This highly conserved sequence presents slight variations among each individual HPV type that allows its genomic identification by recognition of the viral DNA by specific probes. This slight variation guarantees the detection specificity.

The detection of the product amplified by PCR is carried out by means of a low-density microarray platform: CLART® (Clinical Arrays Technology). The platform is based on a very simple principle, but at the same time cost effective. It consists of a microarray printed at the bottom of a microtiter plate, which simplifies the entire hybridization and visualization process when compared to classic microarray systems.

The CLART® HPV3 detection system is based on the precipitation of an insoluble product in those areas of the microarray where hybridization of amplified products with specific probes occurs. During the PCR, the amplified products are labeled with biotin. After amplification, the products are hybridized to their respective specific probes that are immobilized at specific and known areas of the microarray. These immobilised biotinylated products are recognized by the streptavidin-peroxidase conjugate, thus providing with peroxidase activity to the hybridised products. Peroxidase activity will then metabolise o-Dianisidine and produce an insoluble product which will precipitate in those places where hybridisation occurred.

1- CLARTHPV3 user manual